The MPTP/probenecid model of progressive Parkinson's disease

Methods in Molecular Biology

Volumn 964, Issue , 2013, Pages 295-308

  Carta, Anna R ^a   Carboni, Ezio ^a   Spiga, Saturnino ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Animal model; Neuropathology; Neuroprotection; Parkinson's disease; Preclinical Studies

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; PROBENECID; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; MALE; MOUSE; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CONFOCAL MICROSCOPY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; PARKINSON DISEASE; PROBENECID;

MLCS; MLOWN;

EID: 84878643838     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-251-3_17     Document Type: Article

References (42)

1. Hawkes CH, Del Tredici K, Braak H (2007) Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33:599-614
2. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34
3. Hirsch EC (2000) Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment. Ann Neurol 47:S115-S120
4. Nisbet AP, Foster OJ, Kingsbury A, Eve DJ, Daniel SE, Marsden CD, Lees AJ (1995) Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 66:361-376
5. Goto S, Hirano A, Matsumoto S (1990) Metenkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration. Neurology 40:1051-1056
6. Barcia C, Fernández Barreiro A, Poza M, Herrero MT (2003) Parkinson's disease and inflammatory changes. Neurotox Res 5:411-418
7. Hirsch EC, Hunot S (2009) Neuroin flammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8:382-397
8. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 106:518-526
9. Olanow CW (2007) The pathogenesis of cell death in Parkinson's disease (2007). Mov Disord 22(17):S335-S342
10. Zhou C, Huang Y, Przedborski S (2008) Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 1147:93-104
11. Wakabayashi K, Tanji K, Mori F, Takahashi H (2007) The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27:494-506
12. Meredith GE, Sonsalla PK, Chesselet MF (2008) Animal models of Parkinson's disease progression. Acta Neuropathol 115: 385-398
13. Olanow CW, Kieburtz K, Schapira AH (2008) Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 64(Suppl 2):S101-S110
14. Manning-Bog AB, Langston JW (2007) Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox Res 11:219-240
15. Blandini F, Armentero MT, Martignoni E (2008) The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14(Suppl 2):S124-S129
16. Chesselet MF (2008) In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp Neurol 209:22-27
17. Jenner P (2008) Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 64(Suppl 2):S16-S29
18. Schneider B, Zufferey R, Aebischer P (2008) Viral vectors, animal models and new therapies for Parkinson's disease. Parkinsonism Relat Disord 14(Suppl 2):S169-S171
19. Bezard E, Dovero S, Bioulac B, Gross C (1997) Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol 148:288-292
20. Fornai F, Schlüter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Südhof TC (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A 102:3413-3418
21. Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134:57-66
22. Yazdani U, German DC, Liang CL, Manzino L, Sonsalla PK, Zeevalk GD (2006) Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). Exp Neurol 200:172-183
23. Schintu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR (2009) Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res 16:127-139
24. Schmidt N, Ferger B (2001) Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 108:1263-1282
25. Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4- phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224(4656):1451-1453
26. Zuddas A, Fascetti F, Corsini GU, Piccardi MP (1994) In brown Norway rats, MPP + is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity. Exp Neurol 127:54-61
27. Ricaurte GA, Langston JW, Delanney LE, Irwin I, Peroutka SJ, Forno LS (1986) Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res 376:117-124
28. Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS (2001) Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106:589-601
29. Meredith GE, Totterdell S, Petroske E, Santa Cruz K, Callison RC Jr, Lau YS (2002) Lysosomal malfunction accompanies alphasynuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res 956:156-165
30. Novikova L, Garris BL, Garris DR, Lau YS (2006) Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine/ probenecid model of Parkinson's disease. Neuroscience 140:67-76
31. Spiga S, Serra GP, Puddu MC, Foddai M, Diana M (2006) Morphine withdrawalinduced abnormalities in the VTA: confocal laser scanning microscopy. Eur J Neurosci 17:605-612
32. Spiga S, Lintas A, Migliore M, Diana M (2010) Altered architecture and functional consequences of the mesolimbic dopamine system in cannabis dependence. Addict Biol 15:266-276
33. Drucker-Colín R, García-Hernández F (1991) A new motor test sensitive to aging and dopaminergic function. J Neurosci Methods 39:153-161
34. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19:3248-3257
35. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24:9434-9440
36. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y (1985) A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50:435-441
37. Matsuura K, Kabuto H, Makino H, Ogawa N (1997) Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 73:45-48
38. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30:171-182
39. Fernagut PO, Chalon S, Diguet E, Guilloteau D, Tison F, Jaber M (2003) Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience 116:1123-1130
40. Paxinos G, Franklin KBJ (2001) The Mouse Brain in Stereotaxic Coordinates, 2nd edn. Academic, San Diego
41. Marsden CA, Joseph MH (1986) Biogenic amines. In: Kim CK (ed) HPLC of small molecules, a practical approach. IRL Press, Oxford
42. Carboni E (2003) Microdialysis coupled with electrochemical detection: a way to investigate brain monoamine role in freely moving animals. Methods Mol Med 79:415-432